Bulk-Drug Compounding Market Key Highlights:
- Market Size (2024): USD 11.89 Billion
- Projected Market Size (2034): USD 19.93 Billion
- CAGR (2024-2034): 5.3%
Pricing Analysis:
- Price Growth
- Regional Variations
Market Historic Sales
- Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
- Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
- Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
- Analysis of revenue contributions from different manufacturers in the market.
Bulk-Drug Compounding Market Definition
According to the Food and Drug Administration (FDA), pharmaceutical compounding can be defined as the process of altering, combining, or mixing ingredients to cater to the specific medical requirements of an individual. These services are highly sought after by people unable to use marketed drugs due to medical, physical, or physiological issues. Compounded drugs are generally prepared in small batches based on a personalized prescription. However, in cases where the demand for a particular medication exceeds its market availability, bulk-drug compounding provides optimal solutions.
- According to the Homeland Security and Governmental Affairs Committee data, The past ten years have experienced around 15 drug shortages lasting on an average for 1.5 years. The U.S. alone experienced a 30% increase in new drug shortage between 2021 and 2022.
The bulk drug compounding market not only assists with drug shortages but also helps with issues related to limitations in production capacity, economic conditions, complex manufacturing processes, and raw materials shortages. This is commonly observed in highly sterile preparations that have a short shelf life combined with intricate production and often face a shortage in stock. Despite their immense potential, drug compounding is hindered due to a strict regulatory framework. A compounded version of a medication can only be produced if it is listed on the FDA's drug shortages list. Additionally, drug compounds require a specialized license and can only conduct their practices in an FDA-approved facility.
Another common application of the bulk drug compounding services market is seen in the veterinary sector. A compound from the antiviral drug GS-441524 received FDA approval for the treatment of treat feline infectious peritonitis in June 2024. Bulk compunding of such drugs can mutually benifict the industry players as well as the consumers.
Bulk-Drug Compounding Market Segmentation:
By Product
- Sterile Compounding
- Non-Sterile Compounding
By Form
- Oral
- Topical
- Injectable
- Ophthalmic
- Suppositories
By Therapeutic Area
- Cardiovascular
- Oncology
- Endocrinology
- Pain Management
- Infectious Diseases
- Neurology
- Dermatology
- Others
Bulk-Drug Compounding Market Companies:
- Fogron
- B.Broun Melsungen AG
- Nephron Pharmaceuticals Corporaiton
- Athenex Pharmaceutical Division
- QuVa Pharma
- Fresenius Kabi
- Central Admixture Pharmacy Services Inc.
- PharMEDium
- Avella Speciality Pharmacy
- ImprimisRx
- Edge Pharma
- SCA Pharma
- New England Compounding Center
- Bellevue Pharmacy
- Pharmazone GmbH & Co. KG
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
